MiMedx Group Q2 EPS Estimate Lowered by Northland Securities

MiMedx Group, Inc (NASDAQ:MDXG) – Stock analysts at Northland Securities decreased their Q2 2026 EPS estimates for MiMedx Group in a research report issued to clients and investors on Thursday, February 26th. Northland Securities analyst C. Byrnes now expects that the company will earn $0.01 per share for the quarter, down from their previous forecast of $0.03. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s FY2027 earnings at $0.15 EPS.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%.

MDXG has been the topic of a number of other research reports. Mizuho dropped their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Cantor Fitzgerald lowered their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Finally, UBS Group set a $10.00 price target on shares of MiMedx Group in a research note on Monday. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, MiMedx Group has an average rating of “Moderate Buy” and an average price target of $9.60.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $4.89 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The firm has a market cap of $724.22 million, a price-to-earnings ratio of 15.28 and a beta of 1.59. The stock’s 50-day moving average is $5.70 and its 200-day moving average is $6.58. MiMedx Group has a one year low of $4.78 and a one year high of $8.46.

Hedge Funds Weigh In On MiMedx Group

A number of institutional investors have recently bought and sold shares of MDXG. First Light Asset Management LLC raised its stake in MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after buying an additional 1,725,458 shares during the period. Nantahala Capital Management LLC bought a new stake in MiMedx Group in the 3rd quarter valued at $10,237,000. Marshall Wace LLP raised its stake in MiMedx Group by 864.9% in the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after acquiring an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the 4th quarter valued at $7,134,000. Finally, Disciplined Growth Investors Inc. MN boosted its position in MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock worth $9,656,000 after purchasing an additional 1,022,202 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.